Jul 19 |
Even after rising 48% this past week, Personalis (NASDAQ:PSNL) shareholders are still down 89% over the past three years
|
Jul 15 |
Myriad Genetics (MYGN) Expands in MRD Testing With New Collab
|
Jul 11 |
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
|
Jun 18 |
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
|
Jun 13 |
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
|
Jun 4 |
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
|
May 31 |
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
|
May 22 |
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
|
May 9 |
Personalis, Inc. (NASDAQ:PSNL) Q1 2024 Earnings Call Transcript
|
May 9 |
Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?
|